Amir Goldkorn, MD Discusses Baseline CTC Count as a Prognostic Marker of PSA Response and Progression in mCSPC
Baseline CTC counts were shown to be strong indicators for subsequent therapy response and 2-year progression-free survival.
Source: CancerNetwork - Category: Cancer & Oncology Authors: Amir Goldkorn, MD Source Type: news
More News: Cancer & Oncology